Zobrazeno 1 - 10
of 546
pro vyhledávání: '"Channing J. Der"'
Autor:
Daniel P. Nussbaum, Colin A. Martz, Andrew M. Waters, Alejandro Barrera, Annie Liu, Justine C. Rutter, Christian G. Cerda-Smith, Amy E. Stewart, Chao Wu, Merve Cakir, Cecilia B. Levandowski, David E. Kantrowitz, Shannon J. McCall, Mariaelena Pierobon, Emanuel F. Petricoin, J. Joshua Smith, Timothy E. Reddy, Channing J. Der, Dylan J. Taatjes, Kris C. Wood
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-14 (2024)
Abstract Acquired resistance remains a major challenge for therapies targeting oncogene activated pathways. KRAS is the most frequently mutated oncogene in human cancers, yet strategies targeting its downstream signaling kinases have failed to produc
Externí odkaz:
https://doaj.org/article/f640317b562445dfa0b4f3772b68e0d1
Autor:
Bartosz Mucha, Shuo Qie, Sagar Bajpai, Vincenzo Tarallo, J. Nathaniel Diehl, Frank Tedeschi, Gao Zhou, Zhaofeng Gao, Samuel Flashner, Andres J. Klein-Szanto, Hanina Hibshoosh, Shimonosono Masataka, Olga S. Chajewski, Ireneusz Majsterek, Dariusz Pytel, Maria Hatzoglou, Channing J. Der, Hiroshi Nakagawa, Adam J. Bass, Kwok-Kin Wong, Serge Y. Fuchs, Anil K. Rustgi, Eckhard Jankowsky, J. Alan Diehl
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-18 (2022)
Cytoplasmic accumulation of RNA binding protein, hnRNPK in cancer cells is associated with poor prognosis. Here the authors show that SCFFbxo4 E3 ubiquitin ligase-mediated polyubiquitylation of hnRNPK restricts c-Myc translation and limits cancer pro
Externí odkaz:
https://doaj.org/article/fecd2f81e26b43a3b3aad7932728969f
Autor:
Anna Barkovskaya, Craig M. Goodwin, Kotryna Seip, Bylgja Hilmarsdottir, Solveig Pettersen, Clint Stalnecker, Olav Engebraaten, Eirikur Briem, Channing J. Der, Siver A. Moestue, Thorarinn Gudjonsson, Gunhild M. Mælandsmo, Lina Prasmickaite
Publikováno v:
Molecular Oncology, Vol 15, Iss 8, Pp 2026-2045 (2021)
Cellular phenotype plasticity between the epithelial and mesenchymal states has been linked to metastasis and heterogeneous responses to cancer therapy, and remains a challenge for the treatment of triple‐negative breast cancer (TNBC). Here, we use
Externí odkaz:
https://doaj.org/article/0cf47b80942b4dccb4f54632467c29f1
Autor:
Emily M. J. Fennell, Lucas J. Aponte‐Collazo, Joshua D. Wynn, Kristina Drizyte‐Miller, Elisa Leung, Yoshimi Endo Greer, Paul R. Graves, Andrew A. Iwanowicz, Hani Ashamalla, Ekhson Holmuhamedov, Henk Lang, Donald S. Karanewsky, Channing J. Der, Walid A. Houry, Stanley Lipkowitz, Edwin J. Iwanowicz, Lee M. Graves
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 4, Pp n/a-n/a (2022)
Abstract We recently described the identification of a new class of small‐molecule activators of the mitochondrial protease ClpP. These compounds synthesized by Madera Therapeutics showed increased potency of cancer growth inhibition over the relat
Externí odkaz:
https://doaj.org/article/d148e9686840428483903862c1681076
Autor:
Andrew M. Waters, Tala O. Khatib, Bjoern Papke, Craig M. Goodwin, G. Aaron Hobbs, J. Nathaniel Diehl, Runying Yang, A. Cole Edwards, Katherine H. Walsh, Rita Sulahian, James M. McFarland, Kevin S. Kapner, Thomas S.K. Gilbert, Clint A. Stalnecker, Sehrish Javaid, Anna Barkovskaya, Kajal R. Grover, Priya S. Hibshman, Devon R. Blake, Antje Schaefer, Katherine M. Nowak, Jennifer E. Klomp, Tikvah K. Hayes, Michelle Kassner, Nanyun Tang, Olga Tanaseichuk, Kaisheng Chen, Yingyao Zhou, Manpreet Kalkat, Laura E. Herring, Lee M. Graves, Linda Z. Penn, Hongwei H. Yin, Andrew J. Aguirre, William C. Hahn, Adrienne D. Cox, Channing J. Der
Publikováno v:
Cell Reports, Vol 35, Iss 13, Pp 109291- (2021)
Summary: To identify therapeutic targets for KRAS mutant pancreatic cancer, we conduct a druggable genome small interfering RNA (siRNA) screen and determine that suppression of BCAR1 sensitizes pancreatic cancer cells to ERK inhibition. Integrative a
Externí odkaz:
https://doaj.org/article/24ff658919d8494e80b28117e73c541b
Autor:
Onur Dagliyan, Andrey Krokhotin, Irem Ozkan-Dagliyan, Alexander Deiters, Channing J. Der, Klaus M. Hahn, Nikolay V. Dokholyan
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-8 (2018)
Designing split protein approaches is time consuming and often results in high background activity due to spontaneous assembly. Here the authors present an automated approach which uses a split energy scoring function to identify optimal protein spli
Externí odkaz:
https://doaj.org/article/a9e3a56d1ffe4943ab95cf7844fce53d
Autor:
Irem Ozkan-Dagliyan, J. Nathaniel Diehl, Samuel D. George, Antje Schaefer, Bjoern Papke, Kathleen Klotz-Noack, Andrew M. Waters, Craig M. Goodwin, Prson Gautam, Mariaelena Pierobon, Sen Peng, Thomas S.K. Gilbert, Kevin H. Lin, Onur Dagliyan, Krister Wennerberg, Emanuel F. Petricoin, III, Nhan L. Tran, Shripad V. Bhagwat, Ramon V. Tiu, Sheng-Bin Peng, Laura E. Herring, Lee M. Graves, Christine Sers, Kris C. Wood, Adrienne D. Cox, Channing J. Der
Publikováno v:
Cell Reports, Vol 31, Iss 11, Pp 107764- (2020)
Summary: We address whether combinations with a pan-RAF inhibitor (RAFi) would be effective in KRAS mutant pancreatic ductal adenocarcinoma (PDAC). Chemical library and CRISPR genetic screens identify combinations causing apoptotic anti-tumor activit
Externí odkaz:
https://doaj.org/article/5756388e183142489ccb4823f8985e8f
Autor:
Grace R. Anderson, Peter S. Winter, Kevin H. Lin, Daniel P. Nussbaum, Merve Cakir, Elizabeth M. Stein, Ryan S. Soderquist, Lorin Crawford, Jim C. Leeds, Rachel Newcomb, Priya Stepp, Catherine Yip, Suzanne E. Wardell, Jennifer P. Tingley, Moiez Ali, Mengmeng Xu, Meagan Ryan, Shannon J. McCall, Autumn J. McRee, Christopher M. Counter, Channing J. Der, Kris C. Wood
Publikováno v:
Cell Reports, Vol 20, Iss 4, Pp 999-1015 (2017)
Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize therapeutic responses are unclear. Using CRISPR/Cas9, we system
Externí odkaz:
https://doaj.org/article/a9b233c46180479b811cfec67978789b
Publikováno v:
Cancers, Vol 8, Iss 4, p 45 (2016)
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers with a dismal 7% 5-year survival rate and is projected to become the second leading cause of cancer-related deaths by 2020. KRAS is mutated in 95% of PDACs and is a well-validated
Externí odkaz:
https://doaj.org/article/a84267f6f49b4beca317ac23ed7c4d0e
Autor:
Ye S. Lee, Jennifer E. Klomp, Clint A. Stalnecker, Craig M. Goodwin, Yanzhe Gao, Gaith N. Droby, Cyrus Vaziri, Kirsten L. Bryant, Channing J. Der, Adrienne D. Cox
Publikováno v:
Genes & Cancer. 14:30-49